What Is in the DTaP Vaccine? Ingredients Explained

DTaP vaccine contains three categories of active ingredients: diphtheria toxoid, tetanus toxoid, and purified proteins from the bacterium that causes whooping cough. Beyond those active components, the vaccine includes an aluminum-salt adjuvant to strengthen the immune response, trace amounts of formaldehyde left over from manufacturing, and various stabilizers that differ by brand. Each ingredient has a specific job, and the amounts involved are far smaller than most people expect.

The Three Active Components

The name “DTaP” is an abbreviation that maps directly onto its active ingredients. The “D” stands for diphtheria toxoid, the “T” for tetanus toxoid, and the “aP” for acellular pertussis. A toxoid is a bacterial toxin that has been chemically inactivated so it can no longer cause disease but still looks enough like the real thing that your immune system learns to recognize and fight it. Both the diphtheria and tetanus components work this way: they train the body to neutralize the toxins these bacteria produce, which are the actual cause of illness in both diseases.

The pertussis component is more complex. Rather than using a whole killed bacterium (the older approach), acellular pertussis vaccines use a handful of purified proteins from the surface of Bordetella pertussis, the bacterium responsible for whooping cough. Depending on the manufacturer, a DTaP vaccine contains between one and five of these proteins. The most common are pertussis toxoid (an inactivated form of the toxin the bacterium secretes), filamentous hemagglutinin, pertactin, and fimbriae. These proteins are the parts of the bacterium that the immune system most needs to recognize.

Potency requirements set a floor for how much of each toxoid a dose must contain. European standards, for example, require pediatric DTaP vaccines to deliver well above minimum thresholds for both diphtheria and tetanus potency, and manufacturers’ batches are tested against those specifications before release.¹ Even with reduced antigen doses, studies have shown that the vast majority of children still mount protective antibody responses against all three diseases.²

Why “Acellular” Is the Key Word

Before DTaP existed, children received DTP (sometimes written DTwP), which used a whole killed pertussis bacterium. It worked, but the whole-cell version caused more side effects. The United States switched to acellular pertussis vaccines in the 1990s after accumulating concerns about the safety profile of whole-cell formulations.³

Postmarketing data bore out the rationale for the switch. Rates of reported side effects per 100,000 vaccinations dropped substantially with the acellular version: overall reports fell roughly threefold, fever reports dropped by about three-quarters, and seizure reports fell to about a third of the whole-cell rate.⁴ A trial comparing the two formulations in infants in Senegal confirmed lower rates of local reactions, crying, and fever in the acellular group.⁵

The trade-off, as later sections describe, is that acellular vaccines appear to produce a different pattern of immune memory than whole-cell vaccines. The ingredients are cleaner and better tolerated, but the protection they confer fades faster.

Aluminum Adjuvants

If you injected the purified toxoids and pertussis proteins alone, the immune response would be weak and short-lived. Aluminum salts solve that problem. DTaP vaccines contain either aluminum hydroxide, aluminum phosphate, or a mixture, depending on the brand. These salts act as adjuvants, substances that amplify the immune system’s reaction to the antigens in the vaccine.

Aluminum adjuvants work by adsorbing the antigens onto their surface, which slows their release at the injection site and gives immune cells more time to encounter and process them. The aluminum also helps draw inflammatory cells to the area, jumpstarting the chain of events that leads to long-lasting antibody production.⁶

At the injection site, aluminum-containing vaccines do cause small inflammatory nodules. Research tracking these nodules over time found they appeared within 48 hours, shifted from a neutrophil-rich to a macrophage-rich composition over the following month, and gradually shrank. By about 12 months after an intramuscular injection, the nodules had fully resolved, with no muscle damage or tissue death observed at any point.⁷ The total amount of aluminum in a single DTaP dose is typically in the range of 0.17 to 0.85 milligrams, depending on the brand, far less than what a child encounters through food and water in a typical day.

Formaldehyde and Trace Residuals

Formaldehyde shows up on vaccine ingredient lists and tends to alarm people who associate it with industrial chemicals. In vaccine manufacturing, formaldehyde is the agent used to inactivate the diphtheria and tetanus toxins, turning them into harmless toxoids. A residual trace remains in the final product because removing every last molecule is neither practical nor necessary.

Pharmacokinetic modeling shows why this trace is not a safety concern. After a single dose containing 200 micrograms of formaldehyde (which is actually above what most infant vaccines contain), the substance is cleared from the injection site within about 30 minutes. The resulting peak concentration in the blood amounts to less than 1 percent of the formaldehyde already circulating in the body from normal metabolism. Your body naturally produces and breaks down formaldehyde as part of basic cellular chemistry, so the vaccine’s tiny addition barely registers against that background.⁸

Other residuals vary by manufacturer and can include polysorbate 80 (an emulsifier that helps keep the vaccine’s components evenly distributed), 2-phenoxyethanol (a preservative), and bovine serum albumin or other culture-medium leftovers. These are present in trace quantities. In rare cases, manufacturing residues including proteins from culture media and even minute amounts of antibiotics used during production can trigger allergic reactions in sensitized individuals.⁹

The Gelatin Problem

Gelatin is not a universal ingredient in DTaP, but it has played a consequential role in the vaccine’s history. Some DTaP formulations, particularly those used in Japan during the 1990s, included gelatin as a stabilizer. Research revealed a striking pattern: among children who developed allergic reactions to subsequent vaccines containing gelatin, nearly all had previously received gelatin-containing DTaP. In one study, 98 percent of affected children had received a gelatin-containing formulation, well above the 75 percent market share those products held at the time.¹⁰

A follow-up investigation found that among 87 children who had experienced immediate-type allergic reactions (including anaphylaxis) to various vaccines, 91 percent had IgE antibodies against gelatin. Of those whose DTaP history could be traced, every single one had received a gelatin-containing formulation.¹¹ The conclusion was that gelatin-containing DTaP could sensitize young immune systems, priming them for allergic reactions when they later received live viral vaccines (like MMR or varicella) that contained larger amounts of gelatin. This discovery led manufacturers in several countries to reformulate their DTaP products to be gelatin-free, and most current DTaP vaccines sold in the United States no longer contain it.

Combination Vaccines Built on DTaP

DTaP rarely travels alone anymore. The same vial often contains additional antigens to protect against other diseases, reducing the total number of injections a child needs. Pentavalent vaccines add inactivated polio virus and Haemophilus influenzae type b (Hib) conjugate to the DTaP base. Hexavalent formulations add hepatitis B on top of that. The inactive ingredients in combination products are broadly similar to standalone DTaP, though the total antigen load and the specific adjuvant formulation may differ.

A real-world analysis of adverse event reports in the United States found that hexavalent vaccine reports more frequently involved serious outcomes compared with pentavalent vaccine reports, particularly among the youngest infants (six weeks to four months). Events like apnea and cyanosis were reported more often after the hexavalent formulation.¹² Passive reporting systems like VAERS have well-known limitations: they capture reports, not confirmed causal links, and reporting rates can be influenced by how new or closely watched a product is. Still, the signal is one regulators continue to monitor.

How DTaP’s Ingredients Shape the Durability of Protection

Knowing what is in the vaccine helps explain a pattern that has frustrated public-health officials for years: protection from DTaP fades faster than protection from the older whole-cell vaccine did. The acellular pertussis components, by design, present a narrow set of purified proteins rather than the full bacterial surface. This produces a cleaner immune response with fewer side effects, but it also primes a somewhat different type of immune memory.

Studies tracking vaccinated children over time have documented the decline. One large study found that after the fifth dose of DTaP (typically given around age four to six), the odds of contracting pertussis increased by about 42 percent for each additional year.¹³ A Canadian analysis estimated vaccine effectiveness of roughly 80 percent in the first year after vaccination, dropping to about 41 percent after eight or more years.¹⁴ Children who were primed with the acellular vaccine (rather than the older whole-cell version) had more than double the odds of later pertussis infection, suggesting that the initial series shapes long-term immune memory in ways that matter years down the line.¹⁴

Research points to a mismatch between the immune response DTaP induces and the one triggered by natural infection. DTaP tends to skew toward antibody production without generating the kind of cellular immunity that clears bacteria from the nose and throat. In a baboon study, acellular-vaccinated animals were protected from severe whooping cough symptoms but remained colonized with the bacterium for just as long as unvaccinated animals and transmitted it readily to cage-mates.¹⁵ This finding needs confirmation in humans, but it aligns with the broader observation that acellular vaccines do not appear to generate the mucosal immunity that blocks bacterial carriage in the airways.¹⁶ The waning of T-cell responses has been documented as early as two to three years after booster doses.¹⁷

Pertactin-Deficient Strains and Vaccine-Driven Evolution

One of the more striking consequences of DTaP’s specific ingredient list involves pertactin, a surface protein included in most acellular pertussis vaccines. In recent years, surveillance labs across multiple countries have noticed that an increasing proportion of circulating B. pertussis strains no longer produce pertactin. These strains have acquired mutations that disrupt the gene responsible for making this protein, and the mutations arose independently in different lineages, which is compelling evidence of strong selective pressure from vaccination.¹⁸

The logic is straightforward. Vaccinated populations develop antibodies against pertactin. Bacteria that happen to lack pertactin on their surface escape that antibody pressure and have a survival advantage. Over time, those strains become dominant. Data from Spain tracking isolates from 1986 to 2018 confirmed that pertactin-deficient strains appeared and expanded in proportion to how long acellular vaccines had been in use.¹⁹ In the United States, pertactin-deficient strains now make up the majority of isolates.

Whether this matters clinically is a separate question. Current DTaP formulations contain multiple pertussis antigens, not just pertactin, so losing one target does not render the vaccine useless. But it does erode one layer of protection and adds urgency to efforts to develop next-generation pertussis vaccines that target the bacterium more broadly or induce mucosal immunity.

Tdap in Pregnancy and Antibody Transfer

The adult formulation of the same vaccine is called Tdap (lowercase “d” and “p” indicate lower doses of diphtheria and pertussis antigens). When a pregnant person receives Tdap during the third trimester, maternal antibodies cross the placenta and give the newborn a head start on protection during the first weeks of life, before the infant is old enough to receive DTaP.

Research on antibody transfer found that prenatal Tdap vaccination did not impair the efficiency with which antibodies crossed the placenta but was associated with higher antibody levels in both the mother and the newborn. Infants born to vaccinated mothers were more likely to have protective antibody concentrations, particularly against diphtheria.²⁰ This strategy exists precisely because DTaP’s ingredients take multiple doses to build adequate infant immunity, and the gap between birth and the first dose at two months leaves newborns vulnerable.

How Potency Testing Is Changing

For decades, every batch of DTaP had to prove itself in live-animal challenge tests: laboratory animals were vaccinated and then exposed to diphtheria or tetanus toxin, and survival rates determined whether the batch was potent enough to release. These tests are expensive, ethically problematic, and not particularly precise. An analysis of in vivo potency assays across four DTaP products from different manufacturers found coefficients of variance ranging from 16 percent to 132 percent, meaning the tests themselves introduce enormous variability that makes it hard to distinguish real differences in vaccine quality from random noise.²¹

Newer approaches aim to replace these animal tests with serological methods that measure antibody responses in a single combined assay. One validated protocol immunizes guinea pigs and then measures antibody levels against all three DTaP components simultaneously using electrochemiluminescence, drastically cutting the number of animals required. The method successfully detected batches of diphtheria component that fell below specifications and confirmed dose-response relationships for all three antigens.²² The long-term goal is fully in vitro testing, no animals at all, though that transition is still in progress for most regulatory authorities.